Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bardoxolone Methyl in Alport Syndrome
NCT03019185Phase 3Completed
- Sponsor
- Biogen
- Start
- Mar 2017
- Primary completion
- Oct 2020
- Modality
- Classical Binding Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of bardoxolone methyl in Alport syndrome, sponsored by Biogen. Started Mar 2017; status: completed.
02
Drugs
bardoxolone methyl
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on NCT03019185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03019185.